Outpost Bio is developing AI-driven models to decode human microbiology by combining automated experiments with machine learning, aiming to help pharma, food, and consumer companies design safer and more effective products.

Outpost Bio, a company focused on decoding complex interactions in human biology, has raised a $3.5 million pre-seed round co-led by Merantix Capital and Seedcamp, with participation from OpenSeed VC, Defined, and several strategic family offices and angel investors. 

Human microbiology examines how microbial communities living in and on the body metabolise drugs, process nutrients, and influence health outcomes. Despite being one of the most complex and data-rich areas in biology, it remains difficult for R&D teams to translate this complexity into actionable insights. While many biological frontier models focus primarily on components encoded in human DNA, biological function emerges from interactions across multiple systems. 

Outpost Bio aims to address this gap by developing frontier models at the interaction layer with a focus on human microbiology. Its Lab-in-the-Loop platform combines automated experimentation with machine learning to create a closed feedback loop in which models learn from experimental results and guide subsequent testing.